Literature DB >> 11576847

A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.

Z Einbeigi1, A Bergman, L G Kindblom, T Martinsson, J M Meis-Kindblom, M Nordling, M Suurküla, J Wahlström, A Wallgren, P Karlsson.   

Abstract

The aim of this study was to describe and characterise a founder mutation of the BRCA1 gene in western Sweden. Of 62 families screened for BRCA mutations, 24 had BRCA1 mutations and two had BRCA2 mutations. Tumours that occurred in family members were histologically reviewed and mutational status was analysed using archival paraffin-embedded tissues. The same BRCA1 mutation, 3171ins5, was found in 16 families who were clustered along the western coast of Sweden. Mutation analysis revealed a maternal linkage in 13 families and a paternal linkage in 3. There was complete agreement between mutation analysis results obtained from blood and archival tissues. The penetrance of breast or ovarian cancer by age 70 years was estimated to be between 59 and 93%. There were no differences in survivals between breast or ovarian cancer patients with the mutation and age-matched controls. Thus, a predominant BRCA1 gene founder mutation associated with a high risk of breast and ovarian cancer has been identified and found to occur in a restricted geographical area, thereby allowing timely and cost-effective mutation screening using blood samples or archival histological material.

Entities:  

Mesh:

Year:  2001        PMID: 11576847     DOI: 10.1016/s0959-8049(01)00223-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 3.  Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

Authors:  Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

4.  A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.

Authors:  Annika Bergman; Anna Flodin; Yvonne Engwall; Eva L Arkblad; Kerstin Berg; Zakaria Einbeigi; Tommy Martinsson; Jan Wahlström; Per Karlsson; Margareta Nordling
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.

Authors:  Pål Møller; Lovise Mæhle; Lars F Engebretsen; Trond Ludvigsen; Christoffer Jonsrud; Jaran Apold; Anita Vabø; Neal Clark
Journal:  Hered Cancer Clin Pract       Date:  2010-01-19       Impact factor: 2.857

6.  A hypothesis-generating search for new genetic breast cancer syndromes--a national study in 803 Swedish families.

Authors:  Anna von Wachenfeldt; Annika Lindblom; Henrik Grönberg; Zakaria Einbeigi; Richard Rosenquist; Camilla Gardman; Lennart Iselius
Journal:  Hered Cancer Clin Pract       Date:  2007-03-15       Impact factor: 2.857

Review 7.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

Review 8.  BRCA1/2 associated hereditary breast cancer.

Authors:  Li-song Teng; Yi Zheng; Hao-hao Wang
Journal:  J Zhejiang Univ Sci B       Date:  2008-02       Impact factor: 3.066

9.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

10.  Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families.

Authors:  Gunilla Kanter-Smoler; Kaisa Fritzell; Anna Rohlin; Yvonne Engwall; Birgitta Hallberg; Annika Bergman; Johan Meuller; Henrik Grönberg; Per Karlsson; Jan Björk; Margareta Nordling
Journal:  BMC Med       Date:  2008-04-24       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.